Last updated: September 29, 2026
Vermox is the branded form of mebendazole, an established anthelmintic used against intestinal parasitic infections. Its commercial profile is mature: the core drug is long off patent, generic competition limits pricing power, and standalone Vermox revenue is not publicly disclosed. Value is concentrated in local brands, generic mebendazole supply, public-health procurement, and formulation or channel execution rather than in exclusivity.
What is Vermox and how is mebendazole used?
Vermox contains mebendazole, a benzimidazole antiparasitic medicine. It is used for infections including pinworm, roundworm, whipworm and hookworm, subject to national labeling and prescribing rules.
| Attribute |
Vermox |
| Active ingredient |
Mebendazole |
| Drug class |
Benzimidazole anthelmintic |
| Common strengths |
100 mg tablets; chewable presentations in selected markets |
| Typical treatment setting |
Community, primary care, pediatric and public-health use |
| Major competitors |
Generic mebendazole, albendazole, pyrantel pamoate |
| Regulatory maturity |
Long-established small-molecule product |
| Biosimilar exposure |
None |
| Primary commercial constraint |
Generic substitution and low unit pricing |
Mebendazole acts by disrupting parasite microtubule formation and glucose uptake. The product is generally used in short courses, which limits recurring prescription revenue per patient. Its commercial volume depends more on infection prevalence, household transmission, school-based treatment and public-health programs than on chronic disease prevalence.
What is the FDA regulatory status of Vermox?
The FDA approved mebendazole in the United States in 1974. The original U.S. Vermox product was a 100 mg chewable tablet. The FDA later approved a reformulated mebendazole chewable product under the Emverm brand, which expanded U.S. commercial availability after a prolonged period in which Vermox was not broadly marketed in the country. [1][2]
The U.S. market has since shifted toward generic mebendazole and alternative branded products. FDA regulatory status must be separated into three categories:
- Historical approval of Vermox or mebendazole products.
- Current marketing status of specific national-label products.
- Availability of generic mebendazole under an active application.
A product can remain listed in FDA databases while being discontinued commercially. FDA’s Orange Book records approval and therapeutic-equivalence information, but it does not guarantee active commercial distribution. [1]
Is Vermox still marketed in the United States?
Vermox is not the dominant U.S. commercial brand for mebendazole. U.S. patients and providers have relied on other branded or generic mebendazole products, including Emverm and generic equivalents where available.
The United States is not the main economic center of the Vermox brand. European and other international markets have greater relevance because the Vermox name remains recognized in selected countries and may be sold through prescription or pharmacy channels depending on national rules.
What patents protect Vermox?
No active core composition-of-matter patent is expected to protect mebendazole in major markets. Mebendazole was discovered and commercialized decades ago, placing the basic molecule well beyond ordinary small-molecule patent terms.
The relevant intellectual-property categories are:
| IP category |
Current relevance |
| Core mebendazole composition patent |
Expired |
| Original manufacturing patents |
Expired or commercially weak |
| Historical Vermox formulation patents |
Generally expired |
| New chewable or pediatric formulation claims |
Potentially relevant only if unexpired and jurisdiction-specific |
| Method-of-use patents |
Limited value for established antiparasitic indications |
| Trademark rights |
Potentially active by country |
| Trade dress and packaging |
Local, narrow protection |
| Regulatory exclusivity |
No meaningful current exclusivity for the old molecule |
The practical protection for Vermox is therefore brand recognition, regulatory registrations, supply relationships, pharmacy access and local trademark rights. A new formulation could receive patent protection if it introduced a genuinely novel delivery system, stability profile or dosing technology, but ordinary tablet and chewable presentations generally provide limited strategic barriers once generic products are approved.
How strong is the Vermox patent estate?
The Vermox patent estate is weak as a barrier to generic entry. Its commercial defensibility is materially lower than that of a recently launched small molecule with active composition, formulation and method-of-use patents.
A generic competitor normally needs to address:
- Product approval requirements.
- Bioequivalence or other applicable regulatory standards.
- Manufacturing and quality-system obligations.
- Country-specific labeling.
- Trademark restrictions preventing use of the Vermox name.
It does not generally need to overcome a live, molecule-level patent covering mebendazole itself.
When does Vermox lose exclusivity?
Vermox lost meaningful product exclusivity decades ago. The precise dates differ by jurisdiction because the original patents, regulatory approvals and national implementation rules were not identical.
U.S. exclusivity timeline
| Event |
Timing |
| FDA approval of mebendazole/Vermox-era product |
1974 |
| Core small-molecule patent protection |
Expired decades ago |
| Current generic-entry environment |
Mature |
| Relevant modern exclusivity |
Product-specific and limited |
| Current franchise status |
No meaningful molecule-level exclusivity |
The 1984 Hatch-Waxman framework created abbreviated approval routes for generic drugs, but mebendazole’s age means the key economic issue is not the expiration of a modern patent. It is whether an approved supplier can manufacture and distribute at acceptable cost.
What is the Orange Book status of Vermox?
The Orange Book should be reviewed at the application and product level rather than by brand name alone. Historical mebendazole products may appear as discontinued, while other mebendazole applications remain active or have different marketing status.
The commercial implications are straightforward:
- An Orange Book listing does not establish that Vermox is currently sold.
- A discontinued brand does not eliminate generic competition.
- Any listed patents must be checked for expiration, certification status and relevance to the specific dosage form.
- A generic applicant may use an ANDA pathway when the reference product and regulatory conditions permit.
No major, current Orange Book patent dispute is associated with Vermox comparable to litigation surrounding high-value oncology, immunology or specialty drugs. [1]
Are there Paragraph IV challenges to Vermox?
No major active Paragraph IV campaign is publicly associated with the historic Vermox franchise. Paragraph IV litigation is most commercially important when a branded product has valuable remaining patents and substantial sales. Mebendazole does not present that profile.
Generic applicants can still face regulatory or commercial barriers without patent litigation. These include:
- Limited reference-product supply.
- Manufacturing scale constraints.
- Low expected margins.
- Market-specific registration costs.
- Wholesaler and pharmacy access.
- Demand volatility in antiparasitic treatment.
The absence of prominent Paragraph IV litigation reflects the age and low economic value of the molecule, not a lack of generic substitutability.
What formulations are protected by Vermox?
The commercially relevant Vermox presentations are conventional oral dosage forms. Formulation differentiation is limited.
Tablet and chewable products
Mebendazole 100 mg tablets and chewable tablets can compete on:
- Taste and texture.
- Pediatric acceptability.
- Excipients.
- Stability.
- Packaging.
- Dosing convenience.
These factors can support brand preference, but they rarely create a durable barrier without an active formulation patent or strong regulatory exclusivity.
Suspension and alternative delivery systems
Liquid suspension, orally disintegrating and other pediatric formulations may attract localized competition. Their value depends on national prescribing patterns and whether the formulation improves administration for children.
A reformulated product may obtain separate regulatory approval and may have formulation-specific patent claims. That protection would not extend automatically to the mebendazole molecule or to all oral products.
What is the competitive landscape for Vermox?
Vermox competes in a low-cost anti-infective market with two principal forms of substitution.
| Competitor |
Competitive position |
| Generic mebendazole |
Closest direct substitute |
| Albendazole |
Broad antiparasitic alternative; important in public-health programs |
| Pyrantel pamoate |
Common alternative for selected intestinal worms |
| Local branded mebendazole |
Competes through pharmacy recognition and distribution |
| Public-health procurement products |
Compete on price, tender access and supply reliability |
Albendazole is the most important strategic comparator in mass drug administration. The World Health Organization recommends benzimidazole medicines, including albendazole and mebendazole, for certain soil-transmitted helminth infections. Procurement decisions often prioritize price, tablet availability, dosage suitability and supply continuity over brand identity. [3]
What market dynamics affect Vermox revenue?
Vermox revenue is shaped by volume and distribution rather than price expansion.
Demand drivers
Demand is supported by:
- Persistent intestinal parasite infections.
- Pediatric treatment requirements.
- Household transmission of pinworm.
- School and community treatment programs.
- Pharmacy-led treatment in countries allowing nonprescription supply.
- Public-health procurement in endemic regions.
Demand constraints
Revenue is constrained by:
- Short treatment duration.
- Low annual treatment frequency for individual patients.
- Generic substitution.
- Low unit prices.
- Competition from albendazole and pyrantel.
- National differences in diagnosis and treatment guidelines.
- Periodic supply interruptions.
The market is relatively defensive in volume but weak in pricing. Parasite prevalence can sustain unit demand, while generic competition transfers much of the economic value from the original brand to low-cost manufacturers and distributors.
What is the financial trajectory for Vermox?
No separately reported Vermox revenue, operating profit or regional sales forecast is available in the public financial disclosures of the relevant multinational groups. Vermox is generally included within broader consumer-health, prescription or regional portfolio reporting rather than disclosed as a standalone asset.
The most supportable financial trajectory is:
| Period |
Financial profile |
| Original launch period |
High relative value from first-mover brand and limited competition |
| Patent-expiration period |
Sharp erosion in exclusivity and pricing |
| Mature generic period |
Stable or fluctuating volume with low unit economics |
| Current period |
Brand-specific revenue depends on geography, channel and supply execution |
| Long-term outlook |
Low growth, limited pricing power and possible volume stability in endemic markets |
Revenue risk is asymmetric. A new competitor can reduce price quickly, but a brand owner has limited ability to increase price without losing pharmacy or payer access. Manufacturing efficiency, tender participation and geographic licensing are more important than promotional investment.
What is Vermox’s revenue exposure?
Vermox is unlikely to represent material group-level revenue exposure for a diversified pharmaceutical company unless the product is concentrated in a smaller regional portfolio. For a local licensee or generic manufacturer, however, the drug can have higher strategic importance because:
- It can anchor a broader anti-infective portfolio.
- It may have predictable pharmacy demand.
- It can support public-sector contracts.
- It can share production and distribution infrastructure with albendazole or other essential medicines.
Standalone revenue estimates based on global market reports should be treated cautiously because many reports combine branded and generic mebendazole, albendazole, veterinary products and broader anthelmintic categories.
What manufacturing and IP barriers affect generic entry?
The main barriers are operational rather than patent-based.
Manufacturers must maintain validated processes, control impurity profiles, meet dissolution and content-uniformity standards, and comply with applicable good manufacturing practice requirements. For chewable products, taste masking and tablet robustness can affect patient acceptance and regulatory performance.
Supply economics also matter. Low-priced products may become commercially unattractive if:
- Active pharmaceutical ingredient costs rise.
- A single manufacturer exits.
- Procurement tenders force prices below sustainable levels.
- Regulatory compliance costs increase.
- Demand is seasonal or concentrated in a few countries.
These constraints can reduce the number of active suppliers without restoring branded exclusivity.
What patent litigation and settlement agreements affect Vermox?
No material current patent litigation or settlement agreement is publicly associated with the historic Vermox franchise. The market does not show the litigation pattern common to high-revenue drugs with multiple active Orange Book patents.
Potential disputes are more likely to involve:
- Trademark ownership.
- Local distribution rights.
- Regulatory status.
- Product quality.
- Supply contracts.
- Parallel importation.
- Labeling or advertising claims.
These matters can affect regional sales but generally do not create a global barrier to generic mebendazole.
How does Vermox compare with albendazole?
| Factor |
Vermox/mebendazole |
Albendazole |
| Patent position |
Mature and off-patent |
Mature and off-patent |
| Main use |
Intestinal nematodes, including pinworm |
Broad antiparasitic and public-health use |
| Brand strength |
Strong in selected markets |
Strong in public-health procurement |
| Generic pressure |
High |
High |
| Pricing power |
Low |
Low |
| Biosimilar risk |
None |
None |
| Public-health relevance |
Significant |
Very significant |
| Commercial growth profile |
Mature |
More supported by mass-treatment programs |
Albendazole has broader visibility in global deworming programs, while Vermox can retain regional strength through brand familiarity and retail availability. The two products compete on indication, dosing, procurement rules and local treatment guidelines.
What generic launch scenarios exist for Vermox?
Scenario 1: Continued mature-brand erosion
Generic mebendazole remains available, while Vermox retains a small premium in markets where physicians or pharmacists recognize the brand. Revenue declines gradually as substitution increases.
Scenario 2: Regional brand stabilization
Vermox maintains stable sales in countries with established pharmacy demand, limited generic penetration or strong local distribution. This outcome depends on supply reliability and favorable channel placement.
Scenario 3: Generic price compression
Multiple suppliers enter or expand, reducing prices and narrowing the brand’s share. This is the most likely pressure in tender-driven and highly substitutable markets.
Scenario 4: Pediatric formulation differentiation
A better-tolerated chewable, dispersible or liquid product gains share in pediatric settings. This could support a premium only if the formulation has meaningful clinical or administration advantages.
What licensing deals and geographic rights matter?
Vermox commercial rights are likely to be country-specific and may involve local affiliates, licensees, distributors or consumer-health operators. The economic value of a license depends on:
- Trademark ownership.
- National product registration.
- Prescription versus over-the-counter status.
- Import and manufacturing rights.
- Local pharmacovigilance obligations.
- Tender eligibility.
- Parallel-import exposure.
A regional license can remain profitable even when the molecule is off patent if the licensee controls a recognized trademark and efficient distribution. It is unlikely to support high royalty rates because generic alternatives constrain net sales.
Key Takeaways
- Vermox is the branded form of mature, off-patent mebendazole.
- The FDA approved mebendazole in 1974; current U.S. economics are shaped by generic and alternative branded products.
- No meaningful molecule-level exclusivity remains.
- The Orange Book is relevant for product-specific status, but no major current Vermox patent dispute is evident.
- Paragraph IV litigation is not a central commercial risk for the franchise.
- There is no biosimilar risk because mebendazole is a small molecule.
- Revenue is not separately disclosed and should be analyzed through regional sales, licensing and distribution data.
- The strongest competitors are generic mebendazole, albendazole and pyrantel pamoate.
- Commercial defensibility rests on brand recognition, formulation execution, manufacturing reliability and market access.
- The expected financial profile is mature, low-growth and price-sensitive, with stable demand in endemic and pharmacy-driven markets.
FAQs About Vermox Patent and Market Outlook
Is Vermox a biologic drug?
No. Vermox contains mebendazole, a chemically synthesized small-molecule medicine. Biosimilar regulation does not apply.
Can a generic manufacturer launch mebendazole without a Vermox license?
Generally, yes, if it obtains the required national marketing authorization and complies with trademark, labeling, manufacturing and regulatory requirements. A license to use the Vermox trademark is separate from approval to market generic mebendazole.
Does Vermox have pediatric market protection?
A pediatric chewable or other formulation can have product-specific regulatory or patent protection, but that protection does not automatically cover all mebendazole products. Any remaining rights must be assessed by jurisdiction and application.
Is Vermox sold over the counter?
The status varies by country. Some markets permit pharmacy or nonprescription supply, while others require a prescription. National labeling and pharmacy rules determine the channel.
Is Vermox a high-value pharmaceutical asset?
No, not on a global standalone basis. Its value is more consistent with a mature regional brand or generic portfolio asset than with a protected specialty pharmaceutical franchise.
References
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.
- World Health Organization. (2023). WHO guideline on control and elimination of human schistosomiasis and soil-transmitted helminthiases. World Health Organization.
